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                            INTRODUCTION 
                     Epidural anesthesia was first performed by Spanish military surgeon 
Fidel Pages in 1921 in lumbar region. In 1949 Curbelo used Tuohy equipment for 
continuous blockade. The epidural technique became popular as it had some 
specific advantages over spinal anaesthesia. The feasibility of extended duration 
and differential blockade extended its application into other fields like post 
operative analgesia, chronic pain relief and obstetric pain relief. But some inherent 
negative points of epidural technique like delayed onset and patchy analgesia 
persist. Various attempts have been made to rectify these negative points. 
         Combined spinal-epidural technique got introduced in an attempt to rectify 
this and has become popular. Various additive drugs have been tried along with 
local anaesthetics in an attempt to hasten the  blockade to improve the quality of 
block. 
         Among drugs that have been tried, magnesium sulphate deserves special 
mention. Even though  magnesium sulphate has been used for various other 
purposes, its entry into anaesthetic arnamentorium is new. Magnesium sulphate  
has been described to possess various properties. The potentiation of local 
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anaesthetic drugs is one among them. So my study aims to evaluate the effect of its 
addition to local anaesthetic in epidural blockade.  
                    Along with local anesthetic agent other  additive drugs are 
Epinephrine, Clonidine , Dexmedetomidine, Neostigmine , Ketamine , and 
Benzodiazepines . 
                    Magnesium sulphate a potent antagonist of NMDA receptors when 
used epidurally is claimed to hasten the onset of sensory blockade. Magnesium 
also causes physiological Calcium channel blockade and decreases the 
postoperative opioid requirements.  
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AIM OF THE STUDY 
                    Sole epidural Bupivacaine is becoming  unpopular due to delayed 
onset of sensory blockade. The aim of the study is to add magnesium sulphate  as 
an adjunct to epidural Bupivacaine and evaluate 
1.  The impact of Magnesium sulphate on the quality of the block using the 
following parameters, 
a. Onset of  sensory blockade 
b. Motor blockade quality 
c. Two segment regression time 
d. Post operative analgesia 
2. Impact of Magnesium sulphate on hemodynamic changes. 
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                            EPIDURAL ANAESTHESIA 
         The term epidural analgesia mean a form of Regional Anaesthesia of 
injecting drugs through a catheter placed in the Epidural space. 
         The injection can cause both loss of sensation (anaesthesia) and a loss of pain 
(analgesia) by blocking the transmission of signal through nerve in or near the 
spinal cord. 
 
HISTORY 
        In 1921 Spanish military Surgeon Fidel Pages uses the modern technique of 
Lumbar Epidural anaesthesia. Italian surgeons Prof Achille Mario Dogliotti 
popularized in 1930. Dr. Robert A Hinson, Dr.Waldo B Edward and Dr. James 
L South Worth working in Us Mariana Hospital developed the technique of 
continuous caudal anaesthesia. In 1949 Curbelo used Touhy equipment for 
continuous blockade. 
LOCATION: 
      Between the spinal Dura and the Spinal periosteum lies the Epidural Space. It 
extends from the Foramen magnum to Sacrococcygeal membrane. 
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CONTENTS: 
      It contains Nerve roots, Fat, Blood vessels, lymphatics and valveless venous 
plexus of Baston. 
BOUNDARIES: 
      Posterior: Laminae and Ligamentum flavum. 
      Sides       : Pedicles of the vertebral body and the intervertebral spaces. 
      Anterior : Bodies of the vertebrae, intervertebral discs and Posterior 
longitudinal ligament. 
 
 
Thickness of Ligamentum Flavum: 
                        Cervical        :  1.5-3.0 mm 
                        Thoracic       :  3.0-5.0 mm 
                        Lumbar        :  5.0-6.0 mm 
                       Caudal          :  2.0-6.0 mm 
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        Distance from the skin is about 4-6cm in 80% of the individuals. The Spinal 
canal is roughly triangular in cross section and therefore the space is deepest in the 
midline posterior. The Epidural space is larger in the caudal than the cephalic 
segment. 
       Each spinal nerve as it passes through its intervertebral foramen into the 
paravertebral space carries with it a collar of the fatty aerolar tissue of the epidural 
space. Paravertebral space both serial and controlateraly communicate with each 
other through the epidural space.  
      There is a negative pressure in the epidural space. The proposed reasons for the 
presence of negative pressure are:    The natural effects of Starling forces across 
capillary walls produce a low fluid pressure in all tissues on the basis of oncotic 
pressure, these results in sub-atmospheric pressure and tissue collapse in the spaces 
of the opposing surfaces of the spinal canal. 
      Dural tenting during needle advancement may also contribute to sub-
atmospheric pressure. 
      Sub-atmospheric intrathoracic pressure is thought to contribute to the 
occurrence of sub-atmospheric pressure in the thoracic epidural level. 
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VEINS:   The Epidural space contains a network of veins there run mainly in a 
vertical direction and form 4 main trunks. These trunks communicate freely by 
venous rings at each vertebral level. 
       The epidural veins are valveless and form a connecting link both between the 
pelvic veins below and the cerebral veins below and the cerebral veins above, a 
possible pathway for the spread of bacteria and malignant cells. 
       The increase in CSF pressure that accompanies laughing and straining results 
in part from the shunt of blood from thoracic and abdomen veins into the thin 
walled vertebral veins. The veins of the epidural space will therefore be distended 
if thoracic or abdomen pressure is increased thus having bloody tap. 
 
ARTERIES:   The arteries of the epidural space are relatively insignificant and 
originate from the arteries corresponding to the named veins. The arteries enter at 
each intervertebral foramen lie chiefly in the lateral part of the epidural space and 
supply the adjacent vertebrae, ligament and spinal cord. 
PHYSIOLOGY: 
        After epidural injection the local anaesthetic drug binds to the spinal nerve in 
the epidural spaces, spinal nerve rootlets within the CSF and within the spinal cord. 
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It enters into the CSF by means of Dural sleeves and spinal radicular arteries. 
Some of the drug goes into the paravertebral space and block the nerves. 
 
RESPIRATORY PHYSIOLOGY:          At the midthoracic level of blockade 
Pulmonary function test, Gas exchange and control of breathing are generally 
preserved in patients without preexisting respiratory diseases. 
       Subjective sensation of dyspnea is due to decreased sensation of expansion of 
chest wall with inspiration. However Tidal volume, respiratory rate, minute 
ventilation and lung volumes are maintained in healthy resting patients. Small 
block height will affect accessory respiratory muscle (abdomen and intercostals) 
which plays major role in expiration which in turn reduces peak expiratory flow. 
 
CARDIAC PHYSIOLOGY:           Epidural blockade results in a lesser degree of 
sympathetic block and much CVS stability than Subarchanoid block. Level of 
sensory block is the same as sympathetic block in Epidural. 
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Blockade below T4:    Results in low thoracic and lumbar will cause in a 
peripheral sympathetic blockade with vascular dilation in the pelvis and lower 
limb, then pooling of blood in the abdomen viscera. This will lead to reduced 
venous return thereby reduced cardiac output. Increased activity of cardiac 
sympathetic fibers T1-T4 result in increased cardiac contraction and heart rate. 
This will maintain normal cardiac output. 
 
Blockade above T4:  Will cause decreased Heart rate and contraction by acting at 
cardiac sympathetic fibers T1-T4 will leads to bradycardia and hypotension. 
GASTROINTESTINAL, HEPATIC AND GENITOURINARY 
PHYSIOLOGY: 
        The sympathectomy of epidural anaesthesia results in relaxation of sphincters, 
contraction of bowels and increased secretion caused by parasympathetic 
predominance. Hepatic blood flow is related to mean arterial pressure and thus 
maintained if the patient in hemodynamicaly stable. Likewise renal blood flow and 
perfusion is preserved. 
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BLADDER: Temporary atonia in lumbar epidural block is due to block of S2-S4. 
In continuous epidural blockade bladder to be catheterisied. 
 
HYPOTHERMIA: Common in epidural block is due to heat loss to the cold 
environment due to sympathectomy induced vasodilatation. 
 
NEURO ENDOCRINE EFFECT OF EPIDURAL ANAESTHESIA: 
       Surgical stress is associated with a variety of changes in Endocrine and 
metabolic function including Protein metabolism leads to negative nitrogen 
balance. This stress is prevented by appropriate sensory blockade. 
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PHARMACOLOGY OF BUPIVACAINE 
 
 
              Bupivacaine 
 
     It is an amide local anaesthetic characterized as Pipecoloxylidides. Addition of 
a butyl group to the piperidine nitrogen of mepivacaine results in Bupivacaine. It is 
a chiral drug because of possession of asymmetric carbon atom. 
     It was first synthesized in Swedon by Ekenstam and his colleagues in 1957 and 
used clinically by L.J.Telivuo in 1963. Its molecular weight is 288. 
Mechanism of Action: 
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     It prevents transmission of nerve impulses by inhibiting passage of sodium ions 
through ion selective sodium channels in nerve membranes. They do not alter the 
transmembrane potential or threshold potential.  
PHARMACOKINETICS: 
     It is a weak base that has pka value above physiologic pH 7.4 only 15% exists 
injection, dosage and use of epinephrine. Lung is capable of extracting bupivacaine 
from circulation, which will in nonionised form. Absorption depends on the site of 
limit concentration of drug that reaches systemic circulation. This first pass 
pulmonary extraction is dose dependant suggesting that it becomes saturated 
rapidly. 
Pka                                                             :           8.1 
Protein Binding                  :            95% 
Lipid Solubility        :            28 
Volume of distribution                 :            73 litre 
Clearance of drug from plasma                :            0.417 lit/min 
Elimination half life       :            210 min 
Onset time                  :            10-15 min 
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METABOLISM 
            Slowest metabolism among amide local anaesthetics. It undergoes aromatic 
hydroxylation, N-dealkylation, amide hydrolysis and conjugation. Only the N-
desbutyl bupivacaine has been measured in blood or urine after epidural or spinal 
anaesthesia. Alpha-1 acid glycoprotein is the most important protein binding site of 
bupivacaine. 
 
SIDE EFFECTS 
           Bupivacaine is more cardio toxic than equieffective doses of lignocaine. 
This is manifested by severe ventricular arrhythmias and myocardial depression. 
Bupivacaine blocks cardiac Na+ channels rapidly during systole and dissociates 
more slowly during diastole, so that a significant fraction of Na+ channels remain 
blocked at the end of the diastole. Thus the block by Bupivacaine is cumulative 
and substantially greater. 
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CLINICAL USE 
      Onset of anaesthesia and duration of action are long. Its tendency to provide 
more sensory than motor block has made it popular for providing postoperative 
analgesia. Used mainly for 
 
               Epidural anaesthesia 
               Spinal anaesthesia 
               Infiltration anaesthesia 
               Field block anaesthesia 
               Nerve block anaesthesia 
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PHARMACOLOGY OF MAGNESIUM 
        
Magnesium is a bivalent ion with an atomic weight of 24.312. Human body 
contains 1 mole (24g) of magnesium. It is the fourth common mineral salt in the 
body after phosphorus, calcium and potassium, second intracellular cation after 
potassium. In serum Magnesium is divided into three fractions: 
                                      1) Ionized 
2) Protein bound and 
3) Contained in anion complexes 
These fractions account for 65%, 27% and 8% in serum concentration respectively. 
 
 
CHEMICAL STRUCTURE OF MAGNESIUM SULPHATE 
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PROPERTIES OF MAGNESIUM SULPHATE: 
1) CELLULAR PROPERTIES: 
       Magnesium intervenes in the activation of membrane calcium ATPase 
and Na+K+ATPase  involved in transmembrane ion exchange during 
depolarization and repolarization phases. It acts as a stabilizer of cell 
membrane and intracytoplasmic orgenelles. 
2) ION CHANNELS: 
       It acts as a regulator of different ion channels. It has a competitive 
antagonist action against calcium inflows thereby limiting the outflow of 
calcium from sarcoplasmic reticulum. So it is a calcium blocker and calcium 
channel modulator. 
 
3)  CARDIOVASCULAR SYSTEM: 
      It acts on calcium channels in the myocardial muscle and also acts 
indirectly on the cardiac muscle by inhibiting the calcium uptake on the 
Troponin C of the myocytes and thereby influencing myocardial 
contractility. 
17 
 
     Its vasodilatory action is due to its activation of cyclic AMP. This causes 
reduction in systolic blood pressure. 
Pulmonary vascular resistance is unaltered. 
Coronary vascular resistance is reduced and causes vasodilation. 
 
4) NEUROMUSCULAR TRANSMISSION: 
       It has preponderant presynaptic and postsynaptic effects. Magnesium 
acts competitively in blocking the entry of calcium into the presynaptic 
release of acetylcholine is reduced by magnesium, thereby decreasing the 
effect of acetylcholine on the postsynaptic receptors, which in turn increases 
the threshold of axonal excitation. 
      It also produces progressive inhibition of catecholamine release from the 
adrenal medulla, adrenergic nerve endings and adrenergic post ganglionic 
sympathetic fibers. 
 
5)  RESPIRATORY SYSTEM: 
      It has bronchodilatory action due to the inhibition of smooth muscle 
contraction, histamine release from the mast cells and acetylcholine release 
from the cholinergic nerve endings. 
6) Magnesium is involved in hundreds of enzyme reactions in the body. 
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7) Acts as antagonist of NMDA receptors and this explains its use in post-
operative analgesia. 
8) Magnesium sulphate increases the production of prostaglandins causing 
vasodilatation of the small intracranial vessels which is responsible for its 
anticonvulsant action. 
 
 
CLINICAL USES: 
1) For Severe Preeclampsia and Eclampsia: 
       A loading dose of 4-6gm magnesium sulphate diluted in 100ml of 
normal saline given over 15min intravenously. Then 2gm/hr in 100ml of IV 
infusion (maintain serum levels between4 and 7mEq/L). 
Intermittent injection: 
       4gm given slow IV followed by 10gm,5gm in each buttocks as deep IM 
injection. Then every 4hours 5gm intramuscularly upto 24hours after 
delivery. 
2)  Magnesium sulphate has a tocolytic effect at serum levels of 8-10mEq/L. 
Loading dose of 4-6gm over 20min  intravenously, then after the contraction 
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ceases maintenance is done using 2-4gm per hour intravenously for 12-24 
hours. 
3)   To reduce the stress response during intubation, magnesium sulphate is 
used in the dosage of 30-50mg/kg. intravenously. 
4)    In surgery for Phaeochromocytoma it helps to maintain haemodynamic 
balance because it inhibits the catecholamine release from adrenal medulla 
and adrenergic nerve endings. 
5)    Nephritic Seizures: In children with nephritic seizures, the 50% 
concentration should be diluted to a 20% solution for i.m. injection. The dose 
for children is 20 to 40 mg (0.1 to 0.2 ml of 20% solution)/kg of body 
weight, administered i.m. as needed, to control seizures. 
6)    It is used postoperatively in patients who have undergone Coronary artery 
bypass grafting to reduce the incidence of ventricular arrhythmias. 
7)    It is also used in the treatment of Torsades De Pointes, as intravenously or 
intraosseously in the dosage of 25 to 50 mg/kg (upto 2gm). 
8)    Acute myocardial infarction: Magnesium sulphate is used is used in the 
dose of 2gm intravenously over 5-15 min followed by 18 gm over 24hrs as 
infusion. 
9)    Total Parenteral Nutrition: In total parenteral nutrition, maintenance 
requirements for magnesium are not precisely known. The maintenance dose 
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recommended for adults is 5 to 8 mEq magnesium/L of TPN solution; typical 
daily intake ranges from 0.25 to 0.6mEq/kg/day for infants. For adult ranges 
from 10 to 24 mEq. 
10)    In barium poisoning: 1-2gm is used to counteract the intense muscle 
stimulating effects of barium. 
11)    In refractory bronchial asthma it is used for its bronchodilatory action. 
12)    Hypomagnesemia : in case of mild deficiency 1 gm every 6hours for 4 
doses, in severe cases 1-5gms (2- 10ml of 50% solution) in divided doses, 
repeated until the serum levels are normal. 
13)    Recent studies show its use in Tetanus patients, at a serum concentration 
of 2-4mEq/L, it gives good control of spasms and muscle rigidity. 
14)    Magnesium sulphate is used in the dose of 50 mg intrathecally for 
potentiation of opioid analgesia. 
 
 
PRECAUTIONS: 
          Because magnesium is removed from the body solely by the kidneys, the 
drug should be used with caution in patients with renal impairment. Urine 
output should be maintained at a level of 25-50 ml per hour. Monitoring serum 
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magnesium levels and the patient’s clinical status is essential to avoid the 
consequences of over dosage in toxemia. Clinical indications of a safe dosage 
regimen include the presence of the patellar reflex (knee jerk) and absence of 
respiratory depression (approximately 16 breaths or more/minute). Serum 
magnesium levels usually sufficient to control convulsions range from 3 to 6 
mg/100 ml (2.5 to 5.0 mEq/L). The strength of the deep tendon reflexes begins 
to diminish when magnesium levels exceed 4 mEq/L. Reflexes may be absent at 
10 mEq magnesium/L, where respiratory paralysis is a potential hazard. An 
injectable calcium salt should be immediately available to counteract the 
potential hazards of magnesium intoxication in eclampsia. 
 
    PREPARATIONS AVAILABLE: 
      Parenteral injection: Magnesium sulphate-       10%, 12.5%, 50% 
      For Intravenous use only -                                      4%, 8%. 
      Magnesium sulphate in dextrose :                       1% in 5% dextrose. 
                                                                                          2% in 5% dextrose.  
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           When administered intravenously the onset of action is immediate and 
duration of action is 30 min. on administration by intramuscular route the onset of 
action takes 1hr and duration of action is 3-4 hrs. 
           Storage: 15-30degree centigrade. For IV use concentration of 20%or less 
should be used. Rate of injection should be 1.5ml/hr. 
 
DRUG INTERACTIONS: 
         Central nervous system depressants:  When barbiturates, opiates, general 
anaesthetics, or other  CNS depressants are administered concomitantly with 
magnesium sulphate, dosage of these agents must be carefully adjusted because of 
the additive central depressant effects. 
         Neuromuscular blocking agents: Excessive neuromuscular blockade has 
occurred in patients receiving parenteral magnesium sulfate and a neuromuscular 
blocking agent; these drugs should be administered concomitantly only with 
caution. 
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        Cardiac glycosides: Magnesium salts should be administered with extreme 
caution in digitalized patients, because serious changes in cardiac conduction, 
which can result in heart block, may occur if administration of calcium is required 
to treat magnesium toxicity. 
 
ADVERSE REACTIONS: 
        The adverse effects of parenteraly administered magnesium usually are the 
result of magnesium intoxication. These include flushing, sweating, hypotension, 
depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and 
CNS depression proceeding to respiratory paralysis. Hypocalcaemia with signs of 
tetany secondary to magnesium sulphate therapy for eclampsia, has been reported. 
SYMPTOMS AND TREATMENT OF OVERDOSE: 
       Magnesium intoxication is manifested by a sharp drop in blood pressure and 
respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign to 
detect the onset of magnesium intoxication. In the event of over dosage, artificial 
ventilation must be provided until a calcium salt can be injected i.v. to antagonize 
the effects of magnesium. 
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      In adults i.v. administration of 5 to 10 mEq of 10% of calcium gluconate will 
usually reverse respiratory depression or heart block due to magnesium 
intoxication. In extreme cases, peritoneal dialysis or hemodialysis may be required. 
      Hypermagnesemia in the newborn may require resuscitation and assisted 
ventilation via endotracheal intubation or intermittent positive pressure ventilation, 
as well as i.v. calcium. 
 
                                 NMDA RECEPTORS 
           
  The NMDA receptors is a glutamate activated calcium ionophore that is 
composed of a series of subunits. 
NMDA – mediated behavior: Blockade of the spinal NMDA receptors by 
intrathecal delivery does not alter acute thermal or mechanical threshold. This 
receptors does play an important role in augmenting afferent evoked excitation in 
the face of conditioning stimulation.  
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PHYSIOLOGICAL EFFECTS: 
             Activation of afferent NMDA receptors will initiate the release of 
substance P while blockade of NMDA receptors not AMPA receptors will 
significantly diminish substance P release evoked from small primary afferents. 
This activation by NMDA receptors may reflect both the depolarization of the 
terminal by the ionophore activation. However in the spinal dorsal horn, in the 
absence of conditioning stimulation, the NMDA receptors fail to be functional in 
the presence of Glutamate. This lack of activation reflects at least in the presence 
of Magnesium ions that occupies and occludes the pore at resting membrane 
potentials. In the face of persistent depolarization of the membrane, as with 
frequent stimulation of C fibers, the membrane is adequately depolarized the 
Magnesium block is removed and the channel become functional passing large 
amounts of calcium and associated curre 
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                                     MATERIALS AND METHODS 
                     After approval of the study by our institutional ethics committee, the 
study was conducted on 50 ASA grade I or II patients undergoing elective lower 
abdominal surgeries. Lumbar epidural anesthesia was performed to all the patients. 
The age of the patients ranged from 23- 70 weighing 45-80 kg and height ranging 
from 150 – 172 cm. all patients were thoroughly examines preoperatively. 
Informed consent was obtained from all of them. 
                  In the assessment room, vital parameters like pulse , blood pressure, 
and base line investigations like hemoglobin, urine analysis for albumin and sugar, 
blood sugar ,urea and creatinine and Electrocardiogram were checked. Thorough 
examination of all the systems and airway assessment was done. 
               Exclusion criteria including significant co-existing diseases , long term 
analgesic use, and contraindications to regional anaesthesia such as local infection 
and bleeding diathesis. 
               The patients were randomly allotted to 2 groups each containing 25. 
Group C: 
                 Patients received 19ml of 0.5 % Bupivacaine + 1 ml  normal saline 
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Group S: 
                Patients received 19ml of 0.5 % Bupivacaine + 50 mg of magnesium 
sulphate at L2-L3 space using 17G Tuohy needle and placing epidural catheter at 8 
cm. 
The total   volume of the injecting solution was 20 ml in both groups. In the 
operating theatre Boyles  apparatus emergency drugs and airway devices were kept 
ready. Patients were shifted to operating table. Non invasive blood pressure and 
Electrocardiogram leads were connected to the patient. Preoperative baseline 
 systolic and diastolic blood pressure, pulse rate, oxygen saturation were recorded. 
Patients were cannulated with 18G intravenous  needle and preloaded with 1 litre 
of Ringer Lactate. The patient was placed in right lateral position. The skin over 
the back was prepared with antiseptic solution and draped with sterile towel. After 
infiltrating skin and subcutaneous tissue with local anaesthetic , 17 G Tuohy needle 
inserted at L2-L3 space and epidural catheter inserted and placed in 8 cm. after 
giving test dose of 2% xylocaine with 1:200000 dilution adrenaline were given. 
After checking any change in pulse rate and able to dorsiflex the great toe,  
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the position of the catheter was confirmed. After 20 minutes the prepared  
solution was injected. Then the patient was made to lie down immediately 
and the time of injection of epidural anesthetic was noted. 
 
SENSORY BLOCK: 
               The onset of sensory block was defined as the time between the injection 
of anaesthetic solution and the absence of pain at L1 dermatome level. Sensory 
block was assessed by loss of sensation by pinprick at L1 level. This pinpricking 
continued till the peak block height was reached and the time was noted. The 
duration of sensory block was defined as the time for regression of two segments 
from the maximum block height evaluate by pinprick. Sensory block was checked 
every 10 mins till it reaches two segment regression levels. 
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MOTOR BLOCK: 
               Motor block was assessed bilaterally using the Dorsiflexion of the ankle 
              Assessment of motor block was started immediately after turning the 
patient supine and continued every minute till the patient is unable to dorsiflex the 
ankle joint.                                                 
                       
VITAL SIGNS AND SIDE EFFECTS: 
                Vital parameters like systolic and diastolic blood pressure, pulse rate and 
oxygen saturation were recorded every 2mins for the first 10min and thereafter  
every 5 mins  until the immediate postoperatively period. Hypotension was defined 
as fall in systolic blood pressure more than 30% from the baseline of systolic blood 
pressure less than 90 mmHg. This was managed with intravenous ephedrine in 
incremental dose of 6 mg. 
 
                  Bradycardia was defined as heart rate of less than 60/min. and was 
planned to be managed with IV atropine in incremental doses. Respiratory 
depression was said to be present if respiratory rate was less than 8/min or Oxygen 
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saturation less than 85%. This was planned to be managed with mask ventilation. 
Vomiting if present was planned to be managed with Inj.Ondensetron 8mg 
intravenously. Pruritis was planned to be managed with reassurance or Inj. 
Pheniramine maleate 22.75mg intravenous. Patients were shifted to post anesthesia 
care unit after completion of surgery.  Vital signs were recorded every 15 min in  
the first hour after surgery, 30min for the next 2hrs. And there after every hour for 
the next 3 hours. Patients were shifted to post operative ward after complete 
resolution of motor blockade and stabilization of blood pressure 
 
DURATION OF ANALGESIA: 
               The time at which the patient complained pain was noted. The duration of 
effective analgesia was defined as the period from the epidural injection to the first 
occasion when the patient complained of pain in the postoperative period. 
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         OBSERVATION AND ANALYSIS 
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OBSERVATION AND ANALYSIS 
Of the fifty patients involved, 25 belonged to group C and other 25 belonged 
to group S 
AGE DISTRIBUTION 
   The age distribution in group S 23-73. Age distribution in control group 27-
70.the mean age and age distribution was similar stastically. 
AGE IN YEARS GROUP S GROUP C 
20-40 23 27 
MAXIMUM 73 70 
MEAN 48.33 44.6 
 
Weight distribution 
        Weight distribution in group S 54-80, while in control group 52-72. Mean 
weight of the patients were comparable. 
Weight in kg Group s Group c 
Range 54-80  52-72 
mean 66.32 65.52 
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Height distribution 
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Height distribution 
 
 
 
 
         Height distribution in group S 156-172 cms, while in control group 153-172. 
Mean height in both group patients were comparable. 
Height in cm Group S Group C 
range 156-172 153-172 
mean 164.36 165.08 
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Sensory blockade          
Sensory blockade 
min 
Group C Group S P value 
Onset  13.44± 1.16 5.92±0.70 <0.0001 
 
 
Motor blockade 
Motor blockade Group S Group C P value 
Onset  12.48± 2.67 16.16± 0.94 <0.0001 
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TWO SEGMENT REGRESSION TIME 
TWO SEGMENT 
REGRESSION 
TIME MIN 
GROUP S GROUP C 
MEAN ± SD 145.36±4.97 136.96±8.19 
 
DURATION OF POST-OP ANALGESIA 
DURATION OF 
POST-OP 
ANALGESIA 
MINS 
GROUP S GROUP C 
MEAN ± SD 231.04±12.63 228.48±8.81 
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Percentage of heart rate changes(below the base line level) 
 
 Group s Group c 
Heart rate changes 
% (mean) 
9.84 9.64 
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PARAMETERS GROUP S GROUP C P VALUE 
AGE 48.3± 13.00 44.6±13.213 0.3233 
HEIGHT 165.08±5.445 164.36±5.345 0.639 
WEIGHT 66.32±7.767 65.52±7.428 0.7148 
ONSET OF 
SENSORY 
BLOCK 
5.92±0.702 13.44±1.158 <0.0001 
ONSET OF 
MOTOR BLOCK 
12.48± 2.650 16.16±0.943 <0.0001 
TWO SEGMENT 
REGRESSION 
TIME 
145.36±4.97 136.96±8.19 <0.0001 
DURATION OF 
POST OP 
ANALGESIA 
231.04±12.633 228.48±8.813 0.41 
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 DISCUSSION 
       The primary aim of this study was   to evaluate the effect of adding 
magnesium sulphate to Bupivacaine in Epidural anaesthesia. The safety of 
Epidural magnesium sulphate administred in humans and animals have been 
established. Simpson and Kroin demonstrated in animals that epidural magnesium 
sulphate has a safety profile. 
      The dose of magnesium sulphate used in this study was based on data Tammoy 
Ghatak and Girish Chandra where 50 mg of magnesium sulphate added to epidural 
Bupivacaine. In their study magnesium sulphate has quickens the onset of sensory 
blockade. The duration of post-operative analgesia are also increased.  
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PARAMETERS GROUP S GROUP C P VALUE 
ONSET OF 
SENSORY 
BLOCK 
5.92±0.702 13.44±1.158 <0.0001 
ONSET OF 
MOTOR BLOCK 
12.48± 2.650 16.16±0.943 <0.0001 
 
   In the study group the time of onset of sensory blockade was 5.92±0.702 mins, 
whereas in control group was 13.44±1.158(p value <0.0001) which shows that 
there is a significant difference in the onset time. The addition of magnesium 
sulphate has definitely decrease the sensory onset time. 
      The time of onset of Motor blockade in study group was 12.48±2.670 whereas 
in the control group Motor blockade was 16.16±0.943(p value <0.0001) which 
shows that the difference is   statistically significant. 
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 The mean duration of two segment regression time in study was 145.36±4.974, 
whereas in control group was 136.96±8.19 (p value <0.0001). 
TWO SEGMENT REGRESSION TIME 
TWO SEGMENT 
REGRESSION TIME MIN 
GROUP S GROUP C P VALUE 
MEAN ± SD 145.36±4.97 136.96±8.19 <0.0001 
 
 
DURATION OF POST-OPERATIVE ANALGESIA 
DURATION OF POST 
OP ANALGESIA MINS 
GROUP S GROUP C P VALUE 
MEAN ± SD 231.04±12.63 228.48±8.81 0.4033 
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The duration of Post-operative analgesia was 231.40±12.633 mins in study group 
and 228.48±8.813 in control group (pvalue <0.41) which shows 2 groups 
were not statistically significant. The probability value was detected by unpaired 
two sample student ‘t’ test. 
    This implies that additive of magnesium sulphate to epidural Bupivacaine will 
quickens the onset of sensory  blockade with minimal prolongation of post-
operative analgesia. 
   This correlate the study of T.Ghatak and G. Chandra of addition of epidural 
magnesium sulphate to bupivacaine to reduce the time of onset of sensory 
blockade. 
 
OTHER PARAMETERS 
  The change in Heart rate was 9.84% in study group whereas in control group 
9.64% which shows there is no significant change. The usage of Ephedrine was 
also there is no significant changes. 
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                                           SUMMARY 
       We conducted a double blinded randomized controlled study in 50 patients 
belonging to ASA I and II undergoing elective lower abdominal surgeries to 
evaluate the effect of adding  magnesium sulphate to bupivacaine and bupivacaine 
alone in epidural anaesthesia in KAPV Govt Medical college hospital. For the 
same reason, we divided randomly the patients into two groups of 25 each.  
     Group C received 19 ml of 0.5%  of bupivacaine (95mg) and 1ml of Normal  
saline. 
     Group S received 19 ml of 0.5% of bupivacaine (95 mg) and 1ml of Magnesium 
sulphate (50 mg). 
    The total volume of the injected solution was 20 ml in both groups. The onset of 
sensory and motor blockade, the duration of post-operative analgesia were noted in 
the both the groups . Demographic data were similar in both the groups.  
    We found the onset of sensory blockade was faster in the magnesium group. 
    The duration of post-operative analgesia was slightly prolonged in the study 
group. 
   The incidence of side effects were similar in both the groups. 
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   There is no difference in the change in heart rate and the episode of hypotension 
were also similar in both the groups. 
 
CONCLUSION 
    This study concludes  that epidural magnesium sulphate when added  to 
bupivacaine will shorten the onset of sensory blockade significantly in patients 
undergoing elective lower abdominal surgeries   without increasing the                 
incidence of side effects.       
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REVIEW OF LITERATURE 
            Tanmoy Ghatak, Girish Chandra, Anita Malik has done a study about 
the effect of adding epidural magnesium sulphate and clonidine to bupivacaine in 
patients undergoing lower abdomen surgeries. A total of 90 ASA grade I and II 
patients undergoing lower abdomen surgeries were enrolled to receive either 
magnesium sulphate (group B) or Clonidine (Group C) along with epidural 
bupivacaine  for surgical anesthesia. All patients received 19ml of epidural 
bupivacaine 0.5% along with 50 mg magnesium in group B, 150mcg clonidine in 
group C, whereas in control group (Group A) received same volume of normal 
saline. The onset of sensory blockade was quicker in magnesium (Group B). In 
group C there was prolongation of duration of anaesthesia and sedation with lower 
VAS score. The study explained the probable reason for quicker onset sensory 
blockade in magnesium group is it is a NMDA receptor antagonist. Magnesium 
also has the property of anti noiciceptive effect in animal models. There are no 
additional side effects in both groups. 
        A A Yousef and Y M Amr has demonstrated the effect of adding magnesium 
sulphate to epidural bupivacaine and fentanyl in elective caesarean section using 
combined spinal-epidural anaesthesia. Patients were allocated in two groups of 
ASA I or II. All received 2ml intrathecal 0.5% hyperbaric bupivacaine, 10 ml 
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epidural 0.25% plain bupivacaine with fentanyl 100mcg and the other receive 10 
ml epidural 5% magnesium sulphate. The group received magnesium has faster 
onset of sensory block and greater motor block and muscle relaxation (p<0.05) and 
also later onset of post operative pain. There is no difference in hypotension, 
nausea and vomiting. 
 
          R.Arcioni and S. Palmisami has conducted a study of giving intrathecal 
and epidural magnesium sulphate supplementation of spinal anaesthesia to patients 
undergoing orthopedic surgeries. Patients were randomly assigned to receive 
intrathecal magnesium sulphate(94.5mg 6.3%) epidural magnesium sulphate (2% 
100mg/hr) intrathecal and epidural magnesium sulphate combined or spinal 
anaesthesia (L bupivacaine and sufentanyl) alone . In patients receiving spinal 
anaesthesia with combined intrathecal and epidural magnesium sulphate 
significantly reduces post-operative analgesia requirement. Magnesium sulphate 
alters pain processing and reduces the induction and maintenance of central 
sensitization by blocking the NMDA receptor in the spinal cord. 
         A. Bilir and S. Gulec has conducted with 50 patients undergoing hip surgery 
were enrolled to received either fentanyl(F) or Fentanyl plus magnesium sulphate 
(FM) for  24 hour for epidural analgesia. All patients were equipped with a patient 
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controlled epidural analgesia device and the initial setting of a demand bolus of 
Fentanyl 25mcg, group FM received 50 mg magnesium sulphate epiduraly as an 
initial bolus dose   followed by a continuous 100 mg day. Since Magnesium has 
antinoiciceptive effects in animal and human models of pain, co-administration of 
magnesium for post-operative epidural analgesia results in a reduction in fentanyl 
consumption without any side effects.     
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PROFORMA 
COMPARISION OF EPIDURAL BUPIVACAINE AND BUPIVACAINE- 
MAGNESIUM SULPHATE COMBINATION 
 
NAME                                                                           DATE 
IP NO                                        AGE                           SEX 
HEIGHT                                       WEIGHT 
 
DIAGNOSIS                                                   SURGERY 
 
 
PREANAESTHETIC  EVALUATION 
HISTORY 
NIL ORAL FROM  
PR                           BP 
 
 
CVS                                   RS                                   OTHER SYSTEMS 
 
ii 
 
 
AIRWAY                                             ASA GRADE 
 
 
ANAESTHESIOLOGIST                                         SURGEON 
 
 
INVESTIGATIONS 
Hb                                        URINE                 ALBUMIN 
 
                                                                           SUGAR 
 
BLOOD SUGAR                               UREA                        CREATININE 
 
CXR                                                    ECG 
 
PRELOADING 
GROUP I   : BUPIVACAINE 0.5% 19ml  at L2-L3 SPACE. 
GROUP II : BUPIVACAINE 0.5% 19ml + 50 mg of MAGNESIUM SULPHATE 
iii 
 
    TIME       PR       BP     SPO2 LEVEL OF 
BLOCK 
REMARKS 
      
 
 
 
 
 
iv 
 
ONSET OF SENSORY BLOCK AT L3 FOR PINPRICK  : 
 
ONSET OF MOTOR BLOCKADE FOR ANKLE DORSIFLEXION: 
 
NUMBER OF HYPOTENSION  EPISODE: 
 
TOTAL USAGE OF EPHEDRINE: 
 
HIGHEST SEGMENT ACHIEVED: 
 
TWO SEGMENT REGRESSION TIME: 
 
SIDE EFFECTS: 
 
